Comparative Pharmacology
Head-to-head clinical analysis: GYNAZOLE 1 versus GYNE LOTRIMIN 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNAZOLE 1 versus GYNE LOTRIMIN 3.
GYNAZOLE-1 vs GYNE-LOTRIMIN 3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butoconazole nitrate, an imidazole antifungal agent, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing fungal cell membrane permeability.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
One 100 mg vaginal ovule inserted intravaginally as a single dose.
Intravaginal: one applicatorful (5 g of 2% cream) or one suppository (200 mg) once daily at bedtime for 3 days.
None Documented
None Documented
Terminal elimination half-life is approximately 6-7 days after intravaginal administration, reflecting slow absorption from the vaginal mucosa and prolonged retention in tissues.
Terminal elimination half-life is 3.5–5 hours for topical administration; systemic absorption is minimal (<0.5%), so half-life reflects local clearance.
Primarily as unchanged drug in feces via biliary elimination; <1% excreted renally as metabolites.
Clotrimazole is primarily excreted via feces (biliary elimination) as metabolites, with approximately 0.5% excreted renally as unchanged drug.
Category C
Category C
Azole Antifungal
Azole Antifungal